ISSN: 2455-5479
Archives of Community Medicine and Public Health
Research Article       Open Access      Peer-Reviewed

Human papillomavirus: What we know and what we doing?

Gökhan Doğukan Akarsu1*, Rukiye Höbek Akarsu2, Neslihan Sungur3 and Nur Tufanoğlu3

1Department of Pharmacy Services, Vocational School of Health Services, Yozgat Bozok University, Turkey
2Department of Nursing, Faculty of Health Sciences, Yozgat Bozok University, Turkey
3Department of Medical Biochemistry, Faculty of Medicine, Erciyes University, Turkey
*Corresponding author: Gökhan Doğukan Akarsu, Department of Pharmacy Services, Vocational School of Health Services, Yozgat Bozok University, Turkey, Tel: +905012741044, +385992022869; E-mail:
Received: 27 January, 2023 | Accepted: 02 February, 2023 | Published: 03 February, 2023
Keywords: HPV; Cervical cancer; HPV vaccine; Young adult

Cite this as

Akarsu GD, Akarsu RH, Sungur N, Tufanoğlu N (2023) Human papillomavirus: What we know and what we doing? Arch Community Med Public Health 9(1): 004-010. DOI: 10.17352/2455-5479.000194

Copyright License

© 2023 Akarsu GD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Aim: In this study, it was aimed to determine the thoughts and attitudes of young adults about HPV and HPV vaccines.

Methods: This study was planned as a cross-sectional study to determine the knowledge levels and attitudes of young people living in a settlement in the middle of Turkey about the HPV vaccine. The research was conducted with 870 young adults between 1-30 November 2022.

Results: The average age of the young people participating in the study was 20.49 ± 2.15 years, 60.9% of them were male. 61% have not heard of the PAP-Smear test before, 51.3% do not know what HPV is, only 17.7% have HPV by vaccination, 8% have HPV vaccine, 24.75% 37.9% of them stated that they wanted to have the HPV vaccine and that the HPV vaccine should be free of charge.

Conclusion: It was determined that the knowledge level of young adults about HPV and HPV vaccine, in general, was very low, only one out of four people wanted to be vaccinated against HPV, and the rate of vaccination was very low. Even if the vaccine is free in our country, it is thought that the vaccination rates will be low.


Human papillomavirus is a DNA virus and belongs to a very large family. This virus is sexually transmitted and begins to form warts in the genital area. Some may heal on their own, while others may begin to form precancerous cervical cancer. Although the reason why it does not cause cancer is not fully explained, research continues [1-3].

Although there are screening programs in developed and developing countries, the efficiency of these screening programs in developing countries is questionable. It cannot be said that participation in routine screening programs is sufficient in Turkey. Because this disease is sexually transmitted and if you do not have a different sexual partner, it is thought that you do not need to go for a check-up routinely for this disease. This situation reduces participation in screening programs [4].

The fact that cancers are included in national or international screening programs does not prevent cervical cancer from being fatal. The importance of vaccination in primary health care is obvious in order to prevent the disease before it occurs. The HPV vaccine is in the national vaccination program of many European countries (such as America, and Australia). Although it has been approved in Turkey since 2007, it is not included in the national vaccination program and is not covered by the Social Security Institution (SGK is the name of the social security institution of the Republic of Turkey). However, it is stated that studies on inclusion in the scope of general health insurance have started in Turkey.

At this stage, it is very important to determine the thoughts and attitudes of young people of childbearing age about vaccination. This study, it was aimed to determine the thoughts and attitudes of students about HPV and HPV vaccines and to raise awareness among students.

Materials and methods

Type of research and sample selection

This study was planned as a cross-sectional study in order to determine the knowledge levels and attitudes of young people living in a settlement in the middle of Turkey about HPV vaccine. The research was carried out between 1-30 November 2022. Students between the ages of 18-25, who did not have any chronic diseases, did not have a physical disability, who agreed to participate in the study, and who could speak Turkish were included in the study. All participants who agreed to participate in the study without sampling were included in the study. The research was completed with 870 participants, reaching 80% of the population.

Data collection

The data were collected University campus between 1-30 November 2022. Questionnaires were collected by the researchers by face-to-face interview method. The data were collected by the researchers using a questionnaire prepared in line with the literature. The questionnaire consists of 53 questions, including questions to determine the demographic characteristics of the participants (age, gender, economic status, etc.), knowledge, evaluation and thoughts about the HPV vaccine.

Ethical approval

An application was made to the local ethics committee in the place where the study was conducted and ethical approval was obtained (2022/37/04). Participants in the study were informed about the study and their written and verbal consents were obtained.

Statistical analysis

The data were evaluated with the SPPS 22 package program on the computer. Data were evaluated using numbers, percentages, means and standard deviations.


The average age of the young people participating in the study is 20.49 ± 2.15 years. All of the participants have university education, 50.8% of them are working in the city center, 90.3% are not working, 51.7% have a medium income. 60.9% of the participants are male. In addition, 50.8% of the participants reside in the city, 45.3% of their mothers are primary school graduates, 90.3% are unemployed, 51.7% of them have income equal to their expenses and 98.2% are single Table 1.

Table 2 shows some suggestions for determining the knowledge level of the participants about HPV and the distribution of the answers given to these suggestions.

Table 3 shows the answers given to some suggestions about HPV. Here, it was determined that they did not have precise and accurate information about the coverage and protection of the HPV vaccine, and they had insufficient information.

Table 4 contains some suggestions and answers regarding the situations that someone with HPV or who has had the HPV vaccine will encounter.

In Table 5, the opinions of the participants about the HPV vaccine were given.


Genital warts caused by HPV viruses are evaluated within the scope of screening programs or upon the complaints of the patients, and a decision is made according to the positivity or negativity of the disease. Genital warts turn into cervical cancer when the necessary treatments are not done or during the suppression of the immune system, and serious life-threatening situations are created. But a vaccine that provides great protection against HPV has been found and made available according to different application procedures. In some countries, the HPV vaccine has not been included in the scope of routine vaccination yet and is available for a fee if requested. One of these countries is Turkey. There is no information in the literature that any vaccine provides 100% protection. But it is an undeniable fact that vaccines protect against diseases to a great extent.

What is the reason for not getting the vaccine that provides such great protection? The reason can be considered as high cost and vaccine rejection, the reason of which cannot be understood. We planned this research to determine what this vaccine rejection was based on. We will discuss the data we obtained as a result of the research.

The mean age of the participants in the study was 20.49 ± 2.15 years. The fact that the study was conducted in such a young age group shows that fertility and vaccination are at the healthiest time, which will provide statistically valuable data for future acquaintance with HPV and catching HPV-related diseases, and the opinions of individuals in this age group about vaccination are very important.

It was determined that 7.1% of the participants in the study had a family history of cervical cancer. If we consider that cancers are not only caused by lifestyle and environmental factors, there may also be a genetic predisposition to cervical cancer. 22.7% of the participants stated that they knew that genital warts cause cervical cancer. Gallaspy, et al. [2022]. reported that 24.1% of patients with cervical cancer had a negative HPV test. In other words, we cannot say that all cervical cancer cases are related to (+) HPV. But it can be stated that 75.9% of (+) HPV is related [5].

The PAP-Smear test is a special test used to collect samples for cervical cancer screening. 61% of the participants stated that they had not heard of the PAP-Smear test before. Worse still, 74.7% of women do not know and have never heard of the PAP-Smear test. The PAP-Smear test is performed in cases where there is no structure called the hymen. In Turkey, premarital sexual intercourse is not considered appropriate by the society. The fact that almost all of the students were single suggests that they may not have been interested in this test. Fear of losing the hymen in order to have the test done may cause the test to be unknown among young people. We believe that students should have information about PAP-Smear between their student years and we consider this to be a lack of education.

51.3% of the respondents do not know what HPV is. 36.3% of those who know what HPV is, reported that they had this information by healthcare professionals. 35.4% of the participants reported that they had heard of the HPV vaccine before. 34% of those who heard about the HPV vaccine stated that they received this information from healthcare professionals.

Only 8% of participants are vaccinated with HPV. If we evaluate that HPV can be transmitted sexually, that all of the participants are of childbearing age and are vulnerable to risks, it will be decided that it is necessary to seriously consider this issue. Other countries have similar low HPV vaccination rates [6,7].

However, another result obtained from the study is that only 24.75% of the participants reported that they wanted to be vaccinated against HPV. Those who want it to be free make up 37.9%. Although it is known that HPV increases the prevalence of cervical cancer, we can say that 66.7% of the participants stated that they were not afraid of HPV. It is obvious that the reason for this is the lack of knowledge. In particular, healthcare professionals should inform their patients about the HPV vaccine [8-13].

The conclusions drawn from the propositions we directed to the participants are even more interesting. 52.2% of them know that HPV causes genital warts and cervical cancer. 52.6% think that HPV is only transmitted sexually. Tucker, et al. (2022) mentioned in their study that HPV can be transmitted iatrogenically. He reported that the equipment used was not sufficiently sterilized, or that the sterilization solutions used did not provide the necessary sterilization. Tucke, et al. [2022], on the other hand, reported that contact with people with HPV does not only need to be sexually, but can also be transmitted through body fluids such as saliva. Robins, et al. (2022) also reported in their study that the solutions used to provide sterile that are kept for a long time do not provide sufficient sterilization, the HPV entering the solution gains resistance after a while, and hypochlorous acid (HOCl) is extremely safe for HPV sterilization [14-16].

We asked the participants whether HPV is present in men. In other words, we wanted men to report whether they carry this virus to make them sick, or whether it is the patient himself, and 62.8% of the participants reported that HPV is not in men or they do not have knowledge about this issue. In addition, 37.2% of the participants reported that using condoms protected them from HPV. Whereas, Rezaee, et al. (2022), Bettampadi, et al. (2020), Giuliano, et al. (2008), Donà, et al. (2022), Taumberger, et al. (2022) and Rosen, et al. (2016) reported in their study that men also carry a high risk of disease, and this prevalence is much higher in male sex workers [17-21].

It was also stated that using a condom does not have a direct effect. Of course, this rate can vary across cultures and societies. Extramarital affairs and polygamous partnerships are not welcomed in Turkey. This prevalence may be slightly lower. But that doesn’t mean they don’t exist. 61.4% confirmed our proposition that polygamy increases the risk, and only 3.7% did not directly agree with this proposition. This situation causes the disease to occur in other body fluids such as saliva and iotrogenic factors. When we asked whether every sexually active woman should have regular PAP Smear, 52% of the participants agreed. The rate of those who reject this proposition is 5.7% [22-25].

Only 17.7% of the participants reported that HPV can be prevented by vaccination. It has been stated in many studies that the HPV vaccine greatly reduces the risk against cervical cancer. In the study of the Center for Disease Prevention and Control, Brandt and Stubbs (2022) and Palmer, et al. (2019), it was reported that the HPV vaccine reduces the risk of cervical cancer and provides protection against the disease to a large extent. It can be said that students have a serious lack of knowledge on this subject [26-28].

In our recommendation regarding the application of HPV in infancy, 38.2% reported that HPV vaccine can be applied. In general, this practice is wrong. Because the immune system weakens during pregnancy, infancy and childhood. At this stage, it is more appropriate to do it during adolescence. It is not foreseen that the vaccine is not a live vaccine, and that it is administered together with other vaccines but with a different injector. However, if all adults are vaccinated, the prolongation of the vaccination period in children can be tolerated, but the sooner it is vaccinated, the stronger the immune response and the longer the disease is defined. In addition, the vaccine dose amount in childhood is less than in adults [29-34].

At the same time, it was determined that 22.5% of the participants knew that they would not have cervical cancer even if they had the HPV vaccine, but the vast majority (61.6%) had no idea about this issue. Other data obtained from the study are 13.8% of the participants in Turkey that the HPV vaccine is paid, 15.9% of the people who have the HPV vaccine do not need to have a PAP Smear test, 23.9% of them are that those with HPV should not be vaccinated. 32.6% of them reported that the HPV vaccine did not provide lifelong protection, 13.6% of them thought that the HPV vaccine protected from HPV, 15.4% of them thought that the HPV vaccine was a non-living vaccine, and 23% of them thought that the pregnant women could be vaccinated against HPV [35-42].

When these data are analyzed specifically, it is seen that the participants are generally not informed about HPV and HPV vaccine when it is evaluated that they are the most educated and youngest (millennial children) group in the society. Because only 32.4% of the participants wanted HPV screenings to be added to routine controls. In addition, 39.1% wanted HPV to be free and 46.9% wanted it to be included in the vaccine list by the Ministry of Health.


When our study is evaluated in general, no other study with such a young age group and such a high sample size has been found in the literature. Although societies in general have knowledge about cervical cancer, the cause was not known in our study group in particular. There is a deep uncertainty about what HPV is or what the vaccine actually does. Because family physicians do not provide enough information about HPV or other diseases. In studies, it protects at least 75% of cervical cancer in people of childbearing age. We can easily say that cervical cancer is among the third most common cancer types among women. It is necessary to be more sensitive to HPV, which is one of the biggest causes of not only cervical cancer, but also anal cancers, oral and mucous cancers [43-48].

There is also information that HPV will be included in the general vaccine list by the Turkish Ministry of Health. The current price of the vaccine is high for private use. When we consider that 3 doses are almost equal to 1 minimum wage and the family is at least 4 people, we can understand that the price is very high. But why stay away from a vaccine that has been scientifically proven to provide such great protection against cervical and head and neck cancers? There can be only one explanation. The explanation is that there is not enough information. In public broadcasting tools. While advertising vitamins and mineral supplements on social media, it is necessary to question why the HPV vaccine remains in the background. We have to increase HPV vaccination rates [49,50].

In conclusion, all research on HPV should be supported. The results of this research should be published and the society should be informed. When it is considered that health literacy is not in a real sense, informing health professionals through various conferences and seminars can be effective in preventing head and neck and cervical cancers and reducing the prevalence.

  1. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 1999 Jul 3;354(9172):20-5. doi: 10.1016/S0140-6736(98)12490-X. Erratum in: Lancet. 2015 Oct 10;386(10002):1446. PMID: 10406360.
  2. Wright Jr, T. C., & Schiffman, M. (2003). Adding a test for human papillomavirus DNA to cervical-cancer screening. New England Journal of Medicine, 348(6), 489-490.
  3. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998 Feb 12;338(7):423-8. doi: 10.1056/NEJM199802123380703. PMID: 9459645.
  4. Cinghu S, Anandharaj A, Lee HC, Yu JR, Park WY. FTS (fused toes homolog) a novel oncoprotein involved in uterine cervical carcinogenesis and a potential diagnostic marker for cervical cancer. J Cell Physiol. 2011 Jun;226(6):1564-72. doi: 10.1002/jcp.22486. PMID: 20945372.
  5. Gallaspy CC, Ricks JR, Nair N, Castellano T, Chapple Agç. Describing the prevalence and unique demographic and clinicopathologic features of HPV-negative cervical cancer. 2022.
  6. Miyoshi A, Ueda Y, Yagi A, Kimura T, Kobayashi E, Tasaka K, Todo A, Matsunami K, Matsuoka T, Kimura T. Challenge to improve Japan's deplorable HPV vaccination rate by local government actions. J Obstet Gynaecol Res. 2022 May;48(5):1233-1239. doi: 10.1111/jog.15202. Epub 2022 Mar 10. PMID: 35274421.
  7. White LS, Maulucci E, Kornides M, Aryal S, Alix C, Sneider D, Gagnon J, Winfield EC, Fontenot HB. HPV Vaccination Rates of 7th Grade Students After a Strong Recommending Statement from the School Nurse. J Sch Nurs. 2022 Aug 9:10598405221118824. doi: 10.1177/10598405221118824. Epub ahead of print. PMID: 35942704.
  8. Heffernan C. Encouraging uptake of the HPV vaccine: A guide for nurses. Independent Nurse. 2022; 2022(9): 16-19.
  9. Casey SM, Paiva T, Perkins RB, Villa A, Murray EJ. Could oral health care professionals help increase human papillomavirus vaccination rates by engaging patients in discussions? J Am Dent Assoc. 2023 Jan;154(1):10-23.e17. doi: 10.1016/j.adaj.2022.09.014. Epub 2022 Dec 8. PMID: 36503668.
  10. Davies C, Burns K. HPV vaccination literacy in sexualities education. Sex Education, 1-9. 2022.
  11. Lamot M, Kirbiš A. Vaccine Hesitancy Around the World: The Problem, Prospects, and Future Directions. In The Palgrave Handbook of Global Social Problems. Cham: Springer International Publishing. 2022; 1-22..      
  12. Penick E, Grabert B, Stockton E, Prentice-Dunn H, Ward M, Kirk T, Gilkey M.. Improving HPV Immunization Practices (IHIP): A process improvement project assessing nursing education intervention towards improving HPV vaccination rates among Army Active-Duty Service Members at a large military base (109). Gynecologic Oncology. 2022; 166: S72.
  13. Efua Sackey M, Markey K, Grealish A. Healthcare professional's promotional strategies in improving Human papillomavirus (HPV) vaccination uptake in adolescents: A systematic review. Vaccine. 2022 Apr 26;40(19):2656-2666. doi: 10.1016/j.vaccine.2022.03.054. Epub 2022 Mar 30. PMID: 35367068.
  14. Tucker J, Milici J, Alam S, Ferster APO, Goldenberg D, Meyers C, Goyal N. Assessing nonsexual transmission of the human papillomavirus (HPV): Do our current cleaning methods work? J Med Virol. 2022 Aug;94(8):3956-3961. doi: 10.1002/jmv.27769. Epub 2022 Apr 21. PMID: 35411608.
  15. Visalli G, Currò M, Facciolà A, Riso R, Mondello P, Laganà P, Di Pietro A, Picerno I, Spataro P. Prevalence of human papillomavirus in saliva of women with HPV genital lesions. Infect Agent Cancer. 2016 Aug 26;11(1):48. doi: 10.1186/s13027-016-0096-3. PMID: 27570540; PMCID: PMC5000464.
  16. Robins LI, Clark A, Gafken PR, Alam S, Milici J, Hassan R, Meyers C. Yüksek riskli HPV için bir dezenfektan olarak hipokloröz asit: Etki mekanizmasına bakış. Tıbbi Viroloji Dergisi. 2022.
  17. de Fouw M, Stroeken Y, Niwagaba B, Musheshe M, Tusiime J, Sadayo I, Reis R, Peters AAW, Beltman JJ. Involving men in cervical cancer prevention; a qualitative enquiry into male perspectives on screening and HPV vaccination in Mid-Western Uganda. PLoS One. 2023 Jan 27;18(1):e0280052. doi: 10.1371/journal.pone.0280052. PMID: 36706114; PMCID: PMC9882699.
  18. Landy R, Haber G, Graubard BI, Campos NG, Sy S, Kim JJ, Burger EA, Cheung LC, Katki HA, Gillison ML, Chaturvedi AK. Upper age-limits for US male HPV-vaccination for oropharyngeal cancer prevention: A microsimulation-based modeling study. J Natl Cancer Inst. 2023 Jan 19:djad009. doi: 10.1093/jnci/djad009. Epub ahead of print. PMID: 36655795.
  19. Shin H, Jeon S, Cho I, Park H. Factors Affecting Human Papillomavirus Vaccination in Men: Systematic Review. JMIR Public Health Surveill. 2022 Apr 26;8(4):e34070. doi: 10.2196/34070. PMID: 35471242; PMCID: PMC9092232.
  20. Tota JE, Giuliano AR, Goldstone SE, Dubin B, Saah A, Luxembourg A, Palefsky JM. Anogenital Human Papillomavirus (HPV) infection, seroprevalence, and risk factors for HPV seropositivity among sexually active men participating in a global HPV vaccine trial. Clinical Infectious Diseases. 2022; 74(7): 1247-1256.
  21. Alaraj RA. Knowledge, attitudes, and beliefs about hpv vaccination among men in the inland empire, california: a qualitative analysis. 2022.
  22. Siseho KN, Omoruyi BE, Okeleye BI, Okudoh VI, Amukugo HJ, Aboua YG. Women's perception of cervical cancer pap smear screening. Nurs Open. 2022 May;9(3):1715-1722. doi: 10.1002/nop2.1196. Epub 2022 Mar 4. PMID: 35243808; PMCID: PMC8994960.
  23. Maelissa MM, Rahawarin H, Kailola NE, Latuconsina VZ, Sallatalohy NMA. Pap Smear as Cervical Cancer Screening in Women of Fertility in 2020. Journal Penelitian Pendidikan IPA. 2022; 8(4): 1863-1867.
  24. Winarna NBA, Suratini LR. Correlation between knowledge level and mother's motivation to do pap smear screening. 2022.
  25. Agarwal M, Sinha S, Singh G, Singh S, Ahmad S. Attitude and Perceived Barriers Among Highly Educated Women Towards Cervical Cancer Screening by Pap Smear: An Online Survey. Cureus. 2022 Aug 31;14(8):e28641. doi: 10.7759/cureus.28641. PMID: 36059362; PMCID: PMC9433053.
  26. Rezaee Azhar I, Yaghoobi M, Mossalaeie MM, Kollaee Darabi A, Nejadeh AH, Jamshidi M, Ahani A, Karkhane Mahmoodi M, Ghalichi L, Shabanzadeh A, Ataei-Pirkooh A, Marjani A, Khamseh A, Shafiei M, Hosseini P, Soltani S, Zandi M, Ghafari P, Aboofazeli A, Ghaziasadi A, Jazayeri SM. Prevalence of human papilloma virus (HPV) genotypes between outpatients males and females referred to seven laboratories in Tehran, Iran. Infect Agent Cancer. 2022 Mar 5;17(1):7. doi: 10.1186/s13027-022-00421-7. PMID: 35248145; PMCID: PMC8897875.
  27. Bettampadi D, Villa LL, Ponce EL, Salmeron J, Sirak BA, Abrahamsen M, Rathwell JA, Reich RR, Giuliano AR. Oral human papillomavirus prevalence and type distribution by country (Brazil, Mexico and the United States) and age among HPV infection in men study participants. Int J Cancer. 2020 Jun 1;146(11):3026-3033. doi: 10.1002/ijc.32713. Epub 2019 Nov 1. PMID: 31583681; PMCID: PMC7117984.
  28. Giuliano AR, Lazcano-Ponce E, Villa LL, Flores R, Salmeron J, Lee JH, Papenfuss MR, Abrahamsen M, Jolles E, Nielson CM, Baggio ML, Silva R, Quiterio M. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2036-43. doi: 10.1158/1055-9965.EPI-08-0151. PMID: 18708396; PMCID: PMC3471778.
  29. Donà MG, Giuliani M, Rollo F, Vescio MF, Benevolo M, Giglio A, Giuliani E, Morrone A, Latini A. Incidence and clearance of anal high-risk Human Papillomavirus infection and their risk factors in men who have sex with men living with HIV. Sci Rep. 2022 Jan 7;12(1):184. doi: 10.1038/s41598-021-03913-5. Erratum in: Sci Rep. 2022 Jun 9;12(1):9527. PMID: 34996988; PMCID: PMC8741812.
  30. Rosen BJ, Walter L, Gilman RH, Cabrerra L, Gravitt PE, Marks MA. Prevalence and correlates of oral human papillomavirus infection among healthy males and females in Lima, Peru. Sex Transm Infect. 2016 Mar;92(2):149-54. doi: 10.1136/sextrans-2014-051942. Epub 2015 Aug 14. PMID: 26275415; PMCID: PMC5463743.
  31. Taumberger N, Joura EA, Arbyn M, Kyrgiou M, Sehouli J, Gultekin M. Myths and fake messages about human papillomavirus (HPV) vaccination: answers from the ESGO Prevention Committee. Int J Gynecol Cancer. 2022 Jul 12;32(10):1316–20. doi: 10.1136/ijgc-2022-003685. Epub ahead of print. PMID: 35820716; PMCID: PMC9554067.
  32. Brandt HM, Stubbs AW. Realizing the Promise of HPV Vaccination to Prevent Cancer. Med (N Y). 2022 Jan 14;3(1):3-5. doi: 10.1016/j.medj.2021.12.007. PMID: 35590142.
  33. Centers for Disease Control and Prevention, United States Department of Health and Human Services Reasons to Get Vaccinated
  34. Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, Cruickshank M. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ. 2019 Apr 3;365:l1161. doi: 10.1136/bmj.l1161. PMID: 30944092; PMCID: PMC6446188.
  35. Ferris RL, Westra W. Oropharyngeal Carcinoma with a Special Focus on HPV-Related Squamous Cell Carcinoma. Annu Rev Pathol. 2023 Jan 24;18:515-535. doi: 10.1146/annurev-pathmechdis-031521-041424. PMID: 36693202.
  36. Malik S, Sah R, Muhammad K, Waheed Y. Tracking HPV Infection, Associated Cancer Development, and Recent Treatment Efforts-A Comprehensive Review. Vaccines (Basel). 2023 Jan 1;11(1):102. doi: 10.3390/vaccines11010102. PMID: 36679945; PMCID: PMC9860736.
  37. Illah O, Olaitan A. Updates on HPV Vaccination. Diagnostics (Basel). 2023 Jan 9;13(2):243. doi: 10.3390/diagnostics13020243. PMID: 36673053; PMCID: PMC9857409.
  38. Deshmukh AA, Damgacioglu H, Georges D, Sonawane K, Ferlay J, Bray F, Clifford GM. Global burden of HPV-attributable squamous cell carcinoma of the anus in 2020, according to sex and HIV status: A worldwide analysis. Int J Cancer. 2023 Feb 1;152(3):417-428. doi: 10.1002/ijc.34269. Epub 2022 Sep 16. PMID: 36054026; PMCID: PMC9771908.
  39. Kanzow P, Mielke K, Hrasky V, Wiegand S, Schliephake H, Beutner D, Wiegand A. Oral health in HPV-positive and HPV-negative patients with oropharyngeal squamous cell carcinoma. Frontiers in Oncology. 2023; 13:109.
  40. Landy R, Haber G, Graubard BI, Campos NG, Sy S, Kim JJ, Burger EA, Cheung LC, Katki HA, Gillison ML, Chaturvedi AK. Upper age-limits for US male HPV-vaccination for oropharyngeal cancer prevention: A microsimulation-based modeling study. J Natl Cancer Inst. 2023 Jan 19:djad009. doi: 10.1093/jnci/djad009. Epub ahead of print. PMID: 36655795.
  41. Rasmussen CL, Thomsen LT, Baandrup L, Franzmann MB, Kjær AK, Grupe Larsen L, Kjær SK. Danimarka vulvar kanseri hastalarından oluşan geniş bir kohortta p16 pozitifliği ve kombine HPV/p16 pozitifliği prevalansındaki zaman eğilimleri. Uluslararası Kanser Dergisi. 2023.
  42. Evans AM, Salnikov M, Gameiro SF, Maleki Vareki S, Mymryk JS. HPV-Positive and -Negative Cervical Cancers Are Immunologically Distinct. J Clin Med. 2022 Aug 18;11(16):4825. doi: 10.3390/jcm11164825. PMID: 36013065; PMCID: PMC9410291.
  43. Damgacioglu H, Sonawane K, Chhatwal J, Lairson DR, Clifford GM, Giuliano AR, Deshmukh AA. Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling study. Lancet Reg Health Am. 2022 Apr;8:100143. doi: 10.1016/j.lana.2021.100143. Epub 2021 Dec 15. PMID: 34927126; PMCID: PMC8672648.
  44. Narducci A, Einarson A, Bozzo P. Human papillomavirus vaccine and pregnancy. Can Fam Physician. 2012 Mar;58(3):268-9. PMID: 22423020; PMCID: PMC3303646.
  45. Kennedy C, Gray Brunton C, Hogg R. 'Just that little bit of doubt': Scottish parents', teenage girls' and health professionals' views of the MMR, H1N1 and HPV vaccines. Int J Behav Med. 2014 Feb;21(1):3-10. doi: 10.1007/s12529-013-9356-4. PMID: 24198038.
  46. Singla A, Fatima N. Vaccination in Pregnancy. In Infections and Pregnancy. Springer, Singapore. 2022; 621-628.
  47. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011 Jun 18;377(9783):2085-92. doi: 10.1016/S0140-6736(11)60551-5. PMID: 21684381.
  48. Saxena K, Kathe N, Sardana P, Yao L, Chen YT, Brewer NT. HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US. Hum Vaccin Immunother. 2023 Jan 11:2161253. doi: 10.1080/21645515.2022.2161253. Epub ahead of print. PMID: 36631995.
  49. Aragones A, Gany F, Kaplan A, Bruno D. An opportunity to increase human papillomavirus vaccination rates: Change the guidelines. Hum Vaccin Immunother. 2022 Nov 30;18(6):2136444. doi: 10.1080/21645515.2022.2136444. Epub 2022 Oct 25. PMID: 36282533; PMCID: PMC9746429.
  50. Agana-Norman DF, Berenson AB, Chang M. Impact assessment of a provider-targeted national vaccine messaging campaign on human papillomavirus vaccination rates among US adolescent males. Prev Med. 2022 Nov;164:107228. doi: 10.1016/j.ypmed.2022.107228. Epub 2022 Aug 31. PMID: 36057389.

Help ?